Prediction of outcome after diagnosis of metachronous contralateral breast cancer

BMC Cancer

Table 4 Logistic regression analysis for risk of metastasis in relation to mode of detection and time interval to the second breast cancer

Patients groups	Mode of detection	Cases	Metastasis	OR	OR*	OR**
		No	No (%)	(95% CI)	(95% CI)	(95% CI)
All	Symptomatic	250	98 (39)	2.1 (1.5-3.0)	2.0 (1.3-3.1)	2.1 (1.3-3.3)
No = 674	Asymptomatic	424	99 (23)	1.0	1.0	1.0
				p < 0.0001	p = 0.002	p = 0.002
< 3 years to BC2	Symptomatic	57	30 (53)	2.4 (1.3-4.5)	1.7 (0.71-4.1)	1.7 (0.67-4.2)
No = 186	Asymptomatic	129	41 (32)	1.0	1.0	1.0
				p = 0.008	p = 0.2	p = 0.3
≥ 3 years to BC2	Symptomatic	193	68 (35)	2.2 (1.5-3.4)	2.2 (1.3-3.8)	2.3 (1.3-4.0)
No = 488	Asymptomatic	295	58 (20)	1.0	1.0	1.0
				p < 0.0001	p = 0.003	p = 0.003
< 50 years at BC1	Symptomatic	96	53 (55)	2.2 (1.3-3.9)	1.5 (0.68-3.3)	1.4 (0.62-3.4)
No = 206	Asymptomatic	110	39 (35)	1.0	1.0	1.0
				p = 0.005	p = 0.3	p = 0.4
≥50 years at BC1	Symptomatic	154	45 (29)	1.7 (1.1-2.7)	2.2 (1.2-3.9)	2.3 (1.3-4.1)
No = 468	Asymptomatic	314	60 (19)	1.0	1.0	1.0
				p = 0.01	p = 0.006	p = 0.006

* Adjusted for calendar period (1977-1986, 1987-1996, 1997-2007), age (under vs. over 50 years at diagnosis of BC1), size (mm) of BC1 and BC2, and node status (N0 vs. N+) for BC1 and BC2. No = 471, 138 patients with <3 years to BC2, and 333 patients with ≥3 years to BC2, 158 patients <50 years and 313 ≥50 years.
** Adjusted for HR* and in addition: treatment for BC1 and BC2 (radiotherapy, chemotherapy, endocrine treatment, yes vs. no for each of the variables.). No = 468, 137 patients with <3 years and 331 patients with ≥3 years to BC2, 157 patients <50 years and 311 ≥50 years.
Abbreviations: BC1 first breast cancer, BC2 second breast cancer , CI confidence interval, DDFS distant disease-free survival, N+ lymph node metastases, N0 no lymph node metastases, No number, node status lymph node status, OR odds ratio

ISSN: 1471-2407